BioNTech SE

NASDAQ:BNTX

Biotechnology

Healthcare
$83.26 -1.52%

-$1.41 today

Market cap
$20.64B
Beta
1.32
P/E (TTM)
-16.2
EPS (TTM)
-$4.93
52W Low $79.52High $124.00

Volume 1.24M

Average 1.11M

BNTX Long-term Debt

Borrowings due after more than one year.

BioNTech SENASDAQ: BNTX

Long-term Debt · Q2 FY2026 · quarter ended Jun 2026

Long-term debt rises 19.1% from a year ago

Long-term debt stood at €258.79M at the end of Q2 FY2026, up 19.1% from a year earlier. Over 3 fiscal years it compounded at -44.6% a year.

Context

  • Long-term debt amounted to 1.3% of total assets at the end of Q2 FY2026, up 0.3 pp from a year earlier.
  • Long-term debt increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether long-term debt keeps rising in the next quarterly balance sheet after a +19.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
€258.79M— QoQ
Last fiscal yearDec 2025
€29.89M-86.1% YoY
Year agoJun 2025
€217.2M+19.1% since
Long-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+19.1%——
1 year-86.1%——
3-year CAGR-44.6%——
5-year CAGR——
10-year CAGR——

Long-term Debt history

EUR · from the balance sheet

Latest · FY2025
29.89M EUR
Year-over-year change
-86.1%
4-year CAGR
-35.4%

Long-term Debt vs competitors

How BNTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so long-term debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +19.1% is the 3rd highest of 4, against a peer median of +66.7%.
  • Long-term debt amounts to 1.3% of total assets for BNTX, versus a peer median of 7.2%.
BNTX Competitors
Long-term Debt for BNTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
GMABGenmab A/SJun 2026$4.84B USD——38.7%
IBRXImmunityBio, Inc.Sep 2026$834.94M USD+66.7%+51.3%137.0%
TGTXTG Therapeutics, Inc.Sep 2026$745.63M USD+203.9%+52.6%46.8%
IMCRImmunocore Holdings plcMar 2026$393.66M USD+0.5%+101.8%36.7%
BNTXBioNTech SEJun 2026€258.79M EUR+19.1%-44.6%1.3%
MGNXMacroGenics, Inc.Mar 2026$31.3M USD——14.4%
INCYIncyte CorporationJun 2026$0 USD——0.0%
IOVAIovance Biotherapeutics, Inc.Sep 2026$0 USD——0.0%
XNCRXencor, Inc.Jun 2026$0 USD——0.0%
IMTXImmatics N.V.Mar 2026€0 EUR——0.0%
CGENCompugen Ltd.Mar 2026$0 USD——0.0%
Peer median (excluding BNTX) —+66.7%+52.6%7.2%

Competitors are the stored peer set for BNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents1.69B13.88B11.66B9.76B7.67B
Short-term Investments381.6M189.4M4.89B7.02B7.16B
Net Receivables12.38B7.15B2.34B1.52B984.48M
Inventory502.5M439.6M357.7M283.3M110.65M
Other Current Assets113.4M271.9M280.9M212.7M210.71M
Total Current Assets15.07B21.92B19.53B18.8B16.14B
Property, Plant & Equipment (Net)520.4M821.1M971.6M1.18B1.29B
Goodwill57.8M61.2M362.5M380.6M367.74M
Intangible Assets144.6M158.5M804.1M790.4M1.61B
Long-term Investments21.3M80.2M1.18B1.25B2.49B
Tax Assets0229.6M81.3M81.7M13.49M
Other Non-current Assets14.4M6.5M83.4M36.1M76.97M
Total Non-current Assets758.5M1.36B3.48B3.73B5.84B
Total Assets15.83B23.28B23.01B22.53B21.98B
Account Payables160M204.1M354M426.7M534.67M
Short-term Debt129.9M36M28.1M39.5M52.18M
Tax Payables1.57B595.9M525.5M4.5M0
Deferred Revenue186.1M77.1M353.3M294.9M754.58M
Other Current Liabilities1.44B2.04B809.6M1.76B734.39M
Total Current Liabilities3.48B2.95B2.07B2.52B2.14B
Long-term Debt171.6M176.2M191M214.7M29.89M
Deferred Tax Liabilities66.7M6.2M39.7M42.4M84.26M
Deferred Revenue (Non-current)9M48.4M398.5M183M87.96M
Other Non-current Liabilities208.2M42.1M60.7M155.3M234.5M
Total Non-current Liabilities455.5M272.9M689.9M595.4M621.84M
Total Liabilities3.94B3.22B2.76B3.12B2.76B
Common Stock246.3M248.6M248.6M248.6M258.89M
Retained Earnings9.88B18.83B19.76B19.1B17.95B
Accumulated OCI93.9M(848.9M)(984.6M)(1.33B)(1.46B)
Other Stockholders Equity00000
Minority Interest00000
Total Equity11.89B20.06B20.25B19.41B19.22B
Total Debt301.5M212.2M219.1M254.2M267.29M
Net Debt(1.39B)(13.66B)(11.44B)(9.51B)(7.4B)

BioNTech SE

NASDAQ:BNTX

Intrinsic Alpha fair value

Locked

Current Price

$83.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.